



Will de van der Schueren

ASSOCIATE

EDUCATION

University of Washington
School of Law
J.D. 2023

University of Washington
Biochemistry
B.S. 2012

INDUSTRIES

Biotechnology
Pharmaceuticals

PRACTICES

Patent
Strategic Counseling
Trade Secrets

BAR ADMISSIONS

Washington
United States Patent
and Trademark Office

BACKGROUND

Will's practice focuses on patent prosecution, freedom-to-operate analysis, and due diligence in the life sciences sector. He earned a B.S. in Biochemistry from the University of Washington in 2012. Will received his J.D. from the University of Washington School of Law in 2023, with a Concentration Track in Intellectual Property.

EXPERIENCE

Will's experience includes preparing and prosecuting domestic and international patent applications, as well as conducting patentability, landscape, and freedom-to-operate searches. Will has extensive experience in the life sciences sector and has co-authored seven papers published in peer-reviewed journals.

Prior to joining Seed IP, Will worked for two years as an Associate Scientist at Bluebird Bio in Seattle, and for four years as a Research Technician at the Fred Hutchinson Cancer Research Center. He also spent over a year as an Undergraduate Research Assistant at the University of Washington. During law school, Will worked at Seed IP as a law clerk and was also a member of the University of Washington's Entrepreneurial Law Clinic.

AFFILIATIONS

Will is admitted to the Washington State Bar and is registered to practice before the United States Patent & Trademark Office. He is a member of the Washington State Patent Law Association (WSPLA), Life Sciences British Columbia, and Life Science Washington (LSW).

SELECTED PUBLICATIONS

- (1) Sauer, M.M., Tortorici, M.A., Park, YJ. et al. Structural basis for broad coronavirus neutralization. *Nat Struct Mol Biol* 28, 478–486 (2021). doi.org/10.1038/s41594-021-00596-4
- (2) Marcandalli J, Fiala B, Ols S, et al. Induction of Potent Neutralizing Antibody Responses by a Designed Protein Nanoparticle Vaccine for Respiratory Syncytial Virus. *Cell*. 2019;176(6):1420-1431.e17. doi:10.1016/j.cell.2019.01.046
- (3) Correnti, C.E., Gewe, M.M., Mehlin, C. et al. Screening, large-scale production and structure-based classification of cystine-dense peptides. *Nat Struct Mol Biol* 25, 270–278 (2018). doi.org/10.1038/s41594-018-0033-9
- (4) Correnti, C.E., Laszlo, G.S., de van der Schueren, W.J. et al. Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation. *Leukemia* 32, 1239–1243 (2018). doi.org/10.1038/s41375-018-0014-3
- (5) Peng T, Chanthaphavong RS, Sun S, et al. Keratinocytes produce IL-17c to protect peripheral nervous systems during human HSV-2 reactivation. *J Exp Med*. 2017;214(8):2315-2329. doi:10.1084/jem.20160581
- (6) Koh CY, Wetzel AB, de van der Schueren WJ, Hol WG. Comparison of histidine recognition in human and trypanosomatid histidyl-tRNA synthetases. *Biochimie*. 2014 Nov;106:111-20. doi: 10.1016/j.biochi.2014.08.005. Epub 2014 Aug 20. PMID: 25151410; PMCID: PMC4250371.
- (7) Koh CY, Kim JE, Wetzel AB, et al. Structures of *Trypanosoma brucei* methionyl-tRNA synthetase with urea-based inhibitors provide guidance for drug design against sleeping sickness. *PLoS Negl Trop Dis*. 2014;8(4):e2775. Published 2014 Apr 17. doi:10.1371/journal.pntd.0002775